TY  - GEN
AU  - Jain,Ankit P
AU  - Patel,Krishna
AU  - Pinto,Sneha
AU  - Radhakrishnan,Aneesha
AU  - Nanjappa,Vishalakshi
AU  - Kumar,Manish
AU  - Raja,Remya
AU  - Patil,Arun H
AU  - Kumari,Anjali
AU  - Manoharan,Malini
AU  - Karunakaran,Coral
AU  - Murugan,Saktivel
AU  - Keshava Prasad,T S
AU  - Chang,Xiaofei
AU  - Mathur,Premendu Prakash
AU  - Kumar,Prashant
AU  - Gupta,Ravi
AU  - Gupta,Rohit
AU  - Khanna-Gupta,Arati
AU  - Sidransky,David
AU  - Chatterjee,Aditi
AU  - Gowda,Harsha
TI  - MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma
SN  - 2045-2322
PY  - 2020///1106
KW  - Antineoplastic Agents
KW  - therapeutic use
KW  - Cell Line, Tumor
KW  - Datasets as Topic
KW  - Drug Delivery Systems
KW  - Drug Resistance, Neoplasm
KW  - genetics
KW  - Epithelial-Mesenchymal Transition
KW  - Erlotinib Hydrochloride
KW  - Genomics
KW  - Humans
KW  - MAP Kinase Kinase 1
KW  - antagonists & inhibitors
KW  - Metabolic Networks and Pathways
KW  - Phenotype
KW  - Protein Kinase Inhibitors
KW  - Proteomics
KW  - Squamous Cell Carcinoma of Head and Neck
KW  - drug therapy
KW  - Whole Genome Sequencing
N1  - Publication Type: Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1038/s41598-019-55208-5
ER  -